Current Topics in iPSCs Technology

1. Regulatory and Policy Considerations in iPSC Research 2. HiPSCs for Population Genetics 3. Using Human Induced Pluripotent Stem Cells to Advance Personalized/Precision Medicine 4. hiPSC disease modeling with 3D organoids: Bioengineering perspective 5. The Differentiation of Embryonic Stem Cells and Induced Pluripotent Stem Cells into Airway and Alveolar Epithelial Cells 6. Transplantation of iPSC-derived human kidney organoids 7. An update on clinical applications of iPSCs from a genomic point of view 8. DNA Damage and Replication in Induced Pluripotent Stem Cells 9. Epigenetic modifications in induced pluripotent stem cells to boost myogenic commitment 10. Applications for Induced Pluripotent Stem Cells (iPSC) in Reproductive Medicine 11. iPSCs in Insulin Resistance, Type 2 Diabetes and the Metabolic Syndrome 12. Induced pluripotent stem cells for cystic fibrosis 13. Exploring 15q13.3 Copy Number Variants in iPSCs 14. Human induced pluripotent stem cells for modeling Brugada syndrome 15. iPSCs for Erythromycin Arrhythmogenicity Testing 16. Therapeutic Potential of Induced Pluripotent Stem Cell derived Extracellular Vesicles: Quo Vadis? Terra Incognito 17. Proteomic Approach for Creation of the Protein Marker Panels to Control for Quality of Human Induced Pluripotent Stem Cells (hiPSCs) 18. Application of induced pluripotent stem cells in tissue engineering 19. Application of iPSC-derived secretome in regenerative medicine 20. iPSCs and toxicology: predictive tool for present and future 21. Rejuvenation through iPSCs and reprogramming in vivo and in vitro

Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.

• Ciências da vida: temas gerais
• Biologia Celular (citologia)

?H2AX; 15q13.3 microdeletions; 15q13.3 microduplications; 3D culture; 3D printing; 3D; Acetylation; Action potential; Aging clocks; Aging; Alveolar type 1 cell; Alveolar type 2 cell; Alveolarization; AntagomiRs; Anterior foregut endoderm; Apoptotic bodies; Arrhythmia; Assembloid; Assisted reproductive technologies; Attention deficit hyperactivity disorder; Autism spectrum disorder; Basal progenitor cell; Beneficial therapeutic effect; Biliary tree; Bioengineering; Biofabrication; Biogenesis; Bioimplant; Biomaterial; Brain organoid; Brugada syndrome; CACNB2Cardiac arrest; Calcium imaging; Canalicular; Cardiometabolic disease; Cardiomyocytes; Cardiotoxicity; Cardiovascular disease; Cell cycle; Cell proliferation; Cell therapy; Cell-free therapy; Cellular reprogramming; CFTR modulators; Channelopathy; Chimera; CHRNA7Copy number variation; Chromosomal aberrations; Chromosomal abnormalities; Ciliated cell; CKD; Classification; Clinical application; Club (Clara) cell; Clustered regularly interspaced short palindromic repeats (CRISPRs)Drug-related adverse effect; Copy number variations; Cystic fibrosis; Data integration; Definitive endoderm; Developmental toxicity; Differentiation protocols; Differentiation; Directed differentiation; Disease modeling; DNA damage response (DDR)Embryonic stem cells (ESCs)Genomic instability; DNA damage; DNA methylation clocks; Drug delivery; Drug screening; EMA; Embryonic stem cells; Epigenetic memory; Epigenetics; Epigenomics; ER stress; Erythromycin; ESRD; Ethics; Exosomes; Expression quantitative trait loci (eQTLs)Genome-wide association study (GWAS)Genomics; Extracellular vesicles; FDA; Gene editing; Genetic basis; Genome-wide association studies; Genomic instability; Genomics; Goblet cell; Gonadal development; Guidelines; Heart organoid; Hepatotoxicity; High-throughput screening; High-throughput; HiPSC apoptosis; hiPSC cohort; HiPSC extended culture; HiPSC glycolysis; HiPSC metabolic state; HiPSC overgrowth; HiPSC proteome; Histones; Human based; Human cardiomyocytes; Human genetics; Human germ cell development; Human induced pluripotent stem cell (hiPSC)Multiomics; Human induced pluripotent stem cells (hiPSCs)Hydrogel; Human iPSC-CMs; Human subjects; In vitro arrhythmogenicity; In vitro gametogenesis; In vitro; Induced pluripotency; Induced pluripotent stem cells (iPSCs)Pluripotent stem cells (PSCs)Replication; Induced pluripotent stem cells; Infertility; Informed consent; Inherited cardiac disease; Institutional review board (IRB)Oversight; Insulin resistance; Intellectual disability; Intestine; iPS cells; iPSC-derived cortical neurons; iPSCs; Kidney organoid; Liver organoid; Lung; Mesenchymal stem cells; Mesenchyme; Mesodermal specification; Metabolic syndrome; Metabolomics; Methylation; Microvesicles; miRNA mimics; miRNAs; Model; Mood disorders; MyoD1Myofiber repair; Myogenesis; Myogenic differentiation protocols; Nanofiber; Natural polymers; Nephrotoxicity; Neurotoxicity; Next-generation sequencing; Niche; Nicotinic acetylcholine receptors; Nkx2.1Pseudoglandular; Noncoding DNA; Nucleic acids; Oocyte; Organ on chip; OTUD7A; Ovary; Oxidative stress; Pancreas; Paracrine mechanism; Patch clamp; Personalized medicine; Pharmaceutical discovery; Pharmacogenomics; Physiological or disease traits; Pluripotency markers; Pluripotent stem cells; Point mutations; Policy; Primordial germ cell; Proteomics; Receptor-ligand; Reentry; Regeneration; Regenerative medicine; Regulation; Rejuvenation; Reproduction; Reprogramming; Research donor; Risk loci; RNA sequencing; Saccular; Scaffold; SCN5A; Screening; Secretome; Seizures; Sodium channel; Sodium current; Somatic mutations; Species-specific; Spermatogonial stem cell; Stem cell differentiation; Stem cells; Sudden cardiac death; Surface markers; Synthetic polymers; Testis; Therapeutic agent; Therapy; Tissue engineering; Toxicology; Transcriptomics; Transplantation; Tumorigenesis; Type 2 diabetes; Vascularization